The Cardiff ECMC has helped in bringing together expertise from two Welsh hospitals to deliver a new cancer treatment as part of a clinical trial.
For the first time, the Clinical Research Facility (CRF) at the University Hospital of Wales (UHW), Velindre Cancer Centre’s Clinical Trials Unit (CTU) and TC BioPharm Ltd. have joined forces, to deliver a study looking into an immunotherapy treatment in patients with advanced cancers.
We are delighted to announce our current Expressions of Interest (EOI) call is open
The ECMC Combinations Alliance and the NIHR CRN Industry Alliance are collaborating to support access to multiple molecules from several of our partners. We invite researchers, from both the ECMC and NIHR networks, to submit novel proposals involving one or more of the novel agents tabled below in combination with standard of care chemotherapy, and/or radiotherapy, and/or another novel drug.
The Research Nurse Steering Committee meeting is an exciting opportunity for representative research nurses from each of the ECMC network’s 18 adult and 11 paediatric sites to come together and help inform strategy and decision making.
Do you have an interest and passion in translational science applied within ECMC network cancer clinical trials? If so, the Quality Assurance and Translational Science Group (QATS) Network group needs you
The QATS Network group is seeking volunteers to join its steering committee and help deliver their mission to ‘support and enable ECMCs to conduct translational research to the appropriate levels of quality and regulatory compliance, utilising validated, cutting-edge techniques’.
We caught up with Professors Peter Schmid and Gary Middleton of the TORCMEK study team about the challenges and successes of their ongoing trial.
Q. What is the anticipated patient benefit of the TORCMEK trial?
TORCMEK aims to establish the feasible dose, regimen and efficacy of the mTOR inhibitor AZD2014 and the MEK inhibitor selumetinib when given in combination.
Breast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results published in The Lancet recently. The Cancer Research UK-funded IMPORT LOW trial revealed that five years after treatment, almost all patients were disease free.
The Programme Office has successfully recruited to four new roles: Student Combinations Alliance Assistant, Project Officer, Project Manager (Workforce) and Project Manager (Network Capabilities).
Eleanor (Ellie) Foot is the new Project Officer. Ellie joined the Programme Office at the end of July and will be supporting the team with upcoming projects.
Hannah Brown has been promoted to Project Manager (Workforce), where she will oversee the Nurses and Junior Investigator network groups alongside the PPI advisory group.
The Centre for Drug Development is pleased to announce the successful conclusion of its tender for biomarker delivery for early phase clinical trial work.
The tender included both novel assay development and sample processing. The tender was the first of its kind to be issued to the ECMC network. Positive responses from across the network at the expression of interest stage indicated a strong willingness to consider a new way of working within academia.